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Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, United States of America

Abstract
Mucins have been associated with survival in various cancer patients, but there have been no studies of mucins in small
bowel carcinoma (SBC). In this study, we investigated the relationships between mucin expression and clinicopathologic
factors in 60 SBC cases, in which expression profiles of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC6 and MUC16 in cancer
and normal tissues were examined by immunohistochemistry. MUC1, MUC5AC and MUC16 expression was increased in SBC
lesions compared to the normal epithelium, and expression of these mucins was related to clinicopathologic factors, as
follows: MUC1 [tumor location (p = 0.019), depth (p = 0.017) and curability (p = 0.007)], MUC5AC [tumor location (p = 0.063)
and lymph node metastasis (p = 0.059)], and MUC16 [venous invasion (p = 0.016) and curability (p = 0.016)]. Analysis of 58
cases with survival data revealed five factors associated with a poor prognosis: poorly-differentiated or neuroendocrine
histological type (p,0.001), lymph node metastasis (p,0.001), lymphatic invasion (p = 0.026), venous invasion (p,0.001)
and curative resection (p,0.001), in addition to expression of MUC1 (p = 0.042), MUC5AC (p = 0.007) and MUC16 (p,0.001).
In subsequent multivariate analysis with curability as the covariate, lymph node metastasis, venous invasion, and MUC5AC
and/or MUC16 expression were significantly related to the prognosis. Multivariate analysis in curative cases (n = 45) showed
that SBC with MUC5AC and/or MUC16 expression had a significantly independent high hazard risk after adjusting for the
effects of venous invasion (hazard ratio: 5.6, 95% confidence interval: 1.8–17). In conclusion, the study shows that a
MUC5AC-positive and/or MUC16-positive status is useful as a predictor of a poor outcome in patients with SBC.
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first cloned mucin, MUC1, is an important human tumor antigen,
ranking second after WT1 [8]. Using immunohistochemistry
(IHC), we have shown that MUC1 and/or MUC4 expression is
related to a poorer prognosis, whereas MUC2 expression is
associated with a better prognosis in various human tumors [7,9].
Aberrant expression of MUC3, MUC4, MUC5AC and MUC6
has been described in pancreatic intraepithelial neoplasia [10,11],
and we recently reported that MUC16 is a candidate as a poor
prognostic factor in cholangiocarcinoma [12].
To date, only two articles have discussed mucins in SBC [13,14]
and the clinical significance of mucin expression in SBC is
unknown. Therefore, the aim of the present study was to

Introduction
Small bowel carcinoma (SBC) is a rare malignancy, in contrast
to colorectal carcinoma. A surgical approach is mainly used to
treat SBC [1–6], but many patients have a poor outcome after
curative resection. Lymph node metastasis [1–3], distant metastasis [6], primary tumor status [2,6] and tumor differentiation [1]
have been reported as prognostic factors in SBC.
Mucins are high molecular weight glycoproteins in which the
core proteins are modified by O-glycoside-linked oligosaccharides
[7]. Eighteen core human mucins (MUC1–MUC8, MUC12,
MUC13, MUC15–17 and MUC19–21) have been identified. The
PLOS ONE | www.plosone.org
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EDTA 100uC 30 min, Ventana Medical Systems, Tucson, AZ,
USA). The sections were incubated with a primary antibody (DF3
diluted 1:50, 37uC, 32 min; Ccp58 diluted 1:200, 37uC, 24 min;
8G7 diluted 1:3000, 37uC, 32 min; CLH2 diluted 1:100, 37uC,
24 min; CLH5 diluted 1:100, 37uC, 24 min; OC125 diluted 1:
100, 37uC, 24 min) in phosphate-buffered saline pH 7.4 (PBS)
with 1% bovine serum albumin and stained on a Benchmark XT
automated slide stainer using a diaminobenzidine detection kit
(ultraView DAB, Ventana Medical Systems).
For MUC3 staining, the sections were treated at 100uC for
10 min in 0.01 M citrate buffer at pH 6.0 and then reduced with
0.01 M dithiothreitol in 0.1 M Tris/HCl buffer (pH 8.0) for
30 min at room temperature and alkylated with 0.025 M
iodoacetamide in 0.1 M Tris/HCl buffer (pH 8.0) for 30 min
[10,15]. They were then incubated with mMUC3-1 at 4uC for
16 h and stained by the avidin-biotin complex method. Reaction
products were not present when hybridoma culture medium,
normal mouse serum, or PBS was used instead of the primary
antibodies.

investigate whether expression of mucins (MUC1, MUC2,
MUC3, MUC4, MUC5AC, MUC6 and MUC16) has prognostic
significance in patients with SBC using specimens obtained from
surgical departments at multiple hospitals.

Materials and Methods
Patients and tissue specimens
Between 1973 and 2011, 60 resected specimens of SBC were
collected from Toyota Kosei Hospital, Chutoen General Medical
Center, Chita City Hospital, Anjo Kosei Hospital, Toyohashi
Municipal Hospital, Japanese Red Cross Nagoya Daiichi Hospital,
Kasugai Municipal Hospital, Handa City Hospital, and Kagoshima-shi Medical Association Hospital. Cancers of the ampulla
of Vater or possible metastatic cancer were excluded from the
study. The patients were 28 men and 32 women with an age range
of 34 to 90 (mean 65) years old. The tumor locations were the
duodenum (24 cases), jejunum (20), ileum (14), and not specified
(2). This study was conducted in accordance with the guiding
principles of the Declaration of Helsinki. Informed, written
consent was obtained from 6 patients, and was approved by the
Ethics Committee of Kagoshima-shi Medical Association Hospital
(KMAH 2011-02-02). For the other patients without informed
consent, the Institutional Review Board of Toyota Kosei Hospital
(22-ST04), the Ethics Committees of Toyohashi Municipal
Hospital (43-2011), Japanese Red Cross Nagoya Daiichi Hospital
(26-2013), Kasugai Municipal Hospital (157-2013), Chutoen
General Medical Center, Chita City Hospital and Handa City
Hospital, and the hospital director of Anjo Kosei Hospital gave us
their approvals to use the resected specimens (No specified number
in the latter four hospitals), under the strict condition of privacy
protection in relation to personal information of the patients.
The surgical procedures were partial resection of the small
intestine (31 cases), pancreaticoduodenectomy (8), subtotal stomach-preserving pancreaticoduodenectomy (7), pylorus-preserving
pancreaticoduodenectomy (4), ileocecal resection (6), right hemicolectomy (3), and tumor resection (1). Pancreaticoduodenectomies in 19 cases were performed to guarantee a secure surgical
margin and sufficient lymph node dissection because the tumors in
the duodenum were located near the ampulla of Vater. We
confirmed that all resected specimens were small intestinal
carcinomas using macroscopic and microscopic pathological
findings. Lymph node dissection was performed in 55 cases, not
performed in 3 cases, and this information was unknown in 2
cases. Forty-six cases underwent curative resection, 11 cases
received non-curative resection because of distant metastasis found
in the operation, and the details were unknown for 3 cases. Among
the 60 patients, 23 died of primary disease and one died of
metachronous primary advanced gastric cancer with carcinomatous peritonitis. Overall survival was analyzed in 58 patients, but
was unknown in two patients.

Scoring of the staining results
Three blinded investigators (S.H. M.H. and S.Y.) evaluated the
IHC staining data independently. When the evaluation differed
among the three, a final decision was made by consensus. The
results were evaluated based on the percentage of positively
stained carcinoma cells. We evaluated staining of the cytoplasm
and cell membrane, and the carcinoma cells were considered to be
positive when at least one of these components was positive. A
tumor was considered positive if more than 5% of carcinoma cells
were stained, according to our previous studies using 5% as the
cutoff for mucin expression [16–21].

Statistical analysis
The prevalence of expression of each mucin was compared
between cancer lesions and normal epithelium using a chi-square
test. Associations between mucin expression profiles and clinicopathologic factors were also examined by chi-square test. For
survival analysis, a log-rank test was used to select mucins that
were significantly related to prognosis. A Cox proportional hazard
analysis was used to estimate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) in adjusting for the effects of
other clinicopathologic factors. All reported p values are two-sided
and p,0.05 was considered to be significant.

Results
Expression profiles of mucin antigens
In the normal epithelium of the small intestine, none of the 60
cases showed expression of MUC1 (0%, 0/60) or MUC16 (0%,
0/60), but some expressed MUC2 (58.3%, 35/60), MUC3
(73.3%, 44/60), MUC4 (51.7%, 31/60), MUC5AC (15%, 9/60)
and MUC6 (11.7%, 7/60) (Figure 1, Table S1). MUC6 was also
expressed in duodenal Brunner’s glands in most cases. MUC2,
MUC3 and MUC4 showed higher expression in ileum (p = 0.035),
jejunum (p = 0.011), and ileum (p = 0.002), respectively, compared
to other sites (Figure 1, Table S1).
The expression rates in cancer lesions (more than 5% of
carcinoma cells stained) were MUC1, 51.7% (31/60); MUC2,
26.7% (16/60); MUC3, 55% (33/60); MUC4, 51.7% (31/60);
MUC5AC, 33.3% (20/60); MUC6, 10% (6/60) and MUC16,
8.3% (5/60) (Figure 1).

Immunohistochemistry
All specimens were fixed in formalin, embedded in paraffin and
cut into 4-mm thick sections for IHC, in addition to hematoxylin
and eosin (HE) staining. MUC1 was detected by monoclonal
antibody (MAb) DF3 (mouse IgG, Toray-Fuji Bionics, Tokyo,
Japan), MUC2 by MAb Ccp58 (Novocastra), MUC3 by MAb
mMUC3-1 (generated by K. Rousseau and D. M. Swallow),
MUC4 by MAb 8G7 (generated by S. K. Batra), MUC5AC by
MAb CLH2 (Novocastra), MUC6 by MAb CLH5 (Novocastra),
and MUC16 by MAb OC125 (Acris Antibodies GmbH). IHC was
performed by the immunoperoxidase method, as follows. Antigen
retrieval was performed using CC1 antigen retrieval buffer (pH8.5,
PLOS ONE | www.plosone.org
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Figure 1. The expression rate of mucins in tissue. MUC1, MUC5AC and MUC16 showed increased expression; MUC4 and MUC6 showed equal
expression; and MUC2 and MUC3 showed decreased expression in SBC compared to normal epithelium.
doi:10.1371/journal.pone.0086111.g001

MUC5AC expression was marginally related to tumor location
(p = 0.063) and lymph node metastasis (p = 0.059). MUC6
expression was related to lymph node metastasis (high for positive
lymph node metastasis, p = 0.021). MUC16 expression was related
to venous invasion (high for positive venous invasion, p = 0.016)
and curability (high for non-curative resection, p = 0.016).

Changes of MUC expression from normal epithelium to
carcinomas
Compared to the normal epithelium, MUC1 (p,0.001),
MUC5AC (p = 0.019) and MUC16 (p = 0.022) expression was
significantly increased in SBC; MUC4 and MUC6 expression
showed equal expression; and MUC2 (p,0.001) and MUC3
(p = 0.036) expression was significantly decreased in SBC.
Representative mucin expression patterns in the normal
epithelium and cancer tissues are shown in Figure 2. Among
mucins with increased expression in SBC, MUC1 (Figures 2A and
2B) showed apical and cytoplasmic expression in carcinoma cells,
but not in normal epithelium; MUC5AC (Figures 2C and 2D)
showed cytoplasmic expression in carcinoma cells, but not in
normal epithelium; and MUC16 (Figures 2E and 2F) showed
apical expression in carcinoma cells, but not in normal epithelium.
For mucins with equal expression in SBC and normal tissue,
MUC4 (Figures 2G and 2H) and MUC6 (Figures 2I and 2J) both
showed cytoplasmic expression in carcinoma cells and normal
epithelium (insets). Among mucins with decreased expression in
SBC, MUC2 (Figures 2K and 2L) showed supranuclear expression
in normal epithelium, but not in carcinoma cells; and MUC3
(Figures 2M and 2N) showed apical expression in normal
epithelium, but not in carcinoma cells.

Relationship of clinicopathological factors or mucin
expression with survival period
Information on survival was retrieved for 58 cases. The overall
5-year survival rate and the median survival period were 49.7%
and 1.9 years (95% CI: 1.3–3.3), respectively (data not shown).
A log-rank test showed that histological type (poorly differentiated
or neuroendocrine) (p,0.001), positive lymph node metastasis
(p,0.001), positive lymphatic invasion (p = 0.026), positive venous
invasion (p,0.001), and non-curative resection (p,0.001) were
significantly related to a poorer prognosis (Table S3). Expression of
MUC1 (p = 0.042), MUC5AC (p = 0.007) and MUC16 (p,0.001)
was also significantly related to a poorer prognosis (Figure 3, Table
S3). There was no correlation between expression of other mucins
(MUC2, MUC3, MUC4, and MUC6) and survival.

Multivariate analysis of prognostic factors
The above analysis identified MUC1, MUC5AC and MUC16
as candidate prognostic factors in SBC, in addition to five
clinicopathologic factors: histological type, lymph node metastasis,
lymphatic invasion, venous invasion and curative resection. Since
the sample size (n = 58) was too small to estimate the hazard risk
using these clinicopathologic factors as covariates in the same
model and colinearity among these five factors is likely, curability
was chosen as a covariate (Table 1). SBC cases with MUC5AC or
MUC16 expression showed significantly worse prognoses.
MUC16 had the highest HR (HR:10, 95% CI: 2.8–39), but there
were only five MUC16-positive cases.
Since MUC1, MUC5AC and MUC16 showed increased
expression in SBC lesions and were related to a poorer prognosis,

Relationship between MUC expression in cancer cells and
clinicopathologic features
Relationships between mucin expression and clinicopathologic
features are summarized in Table S2. MUC1 expression was
related to tumor location (high for oral side, p = 0.019), invasion
depth (higher for deeper than pSS (pT3), p = 0.017), venous
invasion (high for positive venous invasion, p = 0.038), and
curability (high for non-curative resection, p = 0.007). MUC2
expression was related to tumor location (high for anal side,
p = 0.034), negative lymphatic invasion (p = 0.041) and histological
type (high for mucinous carcinoma, p = 0.005). MUC4 expression
was related to tumor location (high for anal side, p = 0.012).
PLOS ONE | www.plosone.org

3

April 2014 | Volume 9 | Issue 4 | e86111

Mucin Expression in Small Bowel Cancer

showed apical expression in cancer cells, but not in the normal
epithelium (E and F). In mucins with equal expression in SBC, MUC4
showed cytoplasmic expression in normal epithelium and cancer cells
(G and H); and MUC6 showed cytoplasmic expression in normal
epithelium (insets) and cancer cells (I and J). In mucins with decreased
expression in SBCs, MUC2 showed cytoplasmic expression in normal
epithelium, but not in cancer cells (K and L); and MUC3 showed apical
expression in normal epithelium, but not in cancer cells (M and N).
doi:10.1371/journal.pone.0086111.g002

the effect of these mucins in combination was also examined. SBC
cases with MUC5AC and/or MUC16 expression had a significantly worse prognosis (HR: 3.6, 95% CI: 1.5–8.8) (Table 1). This
association remained after adjustment for the effect of venous
invasion (HR: 4.5, 95% CI: 1.8–11), but abated after adjustment
for lymph node metastasis (HR: 2.4, 95% CI: 0.9–6.2) (data not
shown).
For clinical applications, further analyses were conducted in a
subgroup of 45 patients treated by curative resection. One case

Figure 3. The cumulative survival rates of patients with SBC.
The expression of MUC1 (A), MUC5AC (B) and MUC16 (C) were poorer
than those of patients without expression of MUC1 (p = 0.042), MUC5AC
(p = 0.007) and MUC16 (p,0.001), respectively. Survival data were
calculated using the Kaplan-Meier method.
doi:10.1371/journal.pone.0086111.g003

Figure 2. Analysis of the expression of mucins by immunohistochemistry. In mucins with increased expression in SBC, MUC1
showed apical and cytoplasmic expression in cancer cells, but not in the
normal epithelium (A and B); MUC5AC showed cytoplasmic expression
in cancer cells, but not in the normal epithelium (C and D); and MUC16
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Table 1. Survival analysis using Cox proportional hazard models* with incorporation of curability.

Histological type

Lymph node metastasis

Lymphatic invasion

Venous invasion

MUC1

MUC5AC

MUC16

D/T

P-y

HR

95% CI

well, mod

19/49

166.7

1.0

reference

poor, NEC

5/6

4.1

8.0

2.5–26

muc

0/3

9.1

-

-

Negative

7/26

110.8

1.0

reference

Positive

16/28

50.7

4.0

1.6–11

Negative

3/18

53.8

1.0

reference

Positive

21/40

126.1

2.4

0.7–8.7

Negative

8/29

127.5

1.0

reference

Positive

16/29

52.4

3.7

1.4–10

Negative

8/27

100.6

1.0

reference

Positive

16/31

79.4

1.7

0.6–4.6

Negative

11/38

133.1

1.0

reference

Positive

13/20

46.8

2.5

1.1–6.0

Negative

19/53

176.5

1.0

reference

Positive

5/5

3.4

10

2.8–39

MUC1/MUC5AC

MUC1(2) and MUC5AC(2)

7/24

83.3

1.0

reference

MUC1(+) and/or MUC5AC(+)

17/34

96.6

1.6

0.6–4.3

MUC1/MUC16

MUC1(2) and MUC16(2)

8/27

100.6

1.0

reference

MUC1(+) and/or MUC16(+)

16/31

79.4

1.7

0.6–4.6

MUC5AC(2) and MUC16(2)

9/36

131.3

1.0

reference

MUC5AC(+) and/or MUC16(+)

15/22

48.6

3.6

1.5–8.8

MUC5AC/MUC16

*Curability was included in all the statistical models.
NA: not available, D/T: Deaths/Total, P-y: Person-year, HR: Hazard ratio, 95% CI: 95% confidence interval.
doi:10.1371/journal.pone.0086111.t001

Analysis of mucin expression in 58 patients with information on
survival showed that increased expression of MUC1, MUC5AC
and MUC16 in SBC was significantly related to a poorer
prognosis. Therefore, MUC1, MUC5AC and MUC16 were
identified as candidate prognostic factors and subjected to
multivariate survival analysis. MUC1 is overexpressed and
aberrantly glycosylated in most cancers, and elevation of the
MUC1 level plays an important role in tumor invasion and
metastasis [7,9]. A log-rank test in the 58 patients showed that
MUC1 expression was related to poor survival. However, in
multivariate analysis, MUC1 was not related to prognosis. Thus,
compared with many other human neoplasms [7,9], MUC1
expression seems to be of little significance in SBC. In contrast to
MUC1, multivariate analysis showed that MUC5AC or MUC16
expression was significantly related to a worse prognosis in SBC.
This relationship has not been examined previously. MUC5AC or
MUC16 expression was significantly related to poor survival in
patients with SBC, and in 45 patients who underwent curative
resection, cases with MUC5AC and/or MUC16 expression had a
significantly higher hazard risk factor.
Overexpression of MUC5AC has been associated with poor
prognosis of lung cancer, cholangiocarcinoma and pancreatic
cancer [22–24]. However, till date the molecular mechanism of its
functioning is still obscure. The knockdown studies revealed that
MUC5AC overexpression in tumor cells is associated with
increased growth, adhesion, invasion of tumor cells and increased
metastatic tendency [25–27]. Further, it is associated with lower
infiltration of B cells and neutrophils at metastatic sites [26]. And,
Inaguma et al., observed that GLI1-upregulated MUC5AC
facilitates the migration and invasion of pancreatic cancer cells

without outcome data was excluded from the total of 46 patients
treated by curative resection (Table S2). In the 45 cases,
MUC5AC and/or MUC16 expression was a significant independent high hazard risk after adjustment for the effect of venous
invasion as a covariate (Model 1 in Table 2, HR: 5.6, 95% CI:
1.8–17), but not for the effect of lymph node metastasis as a
covariate (Model 2 in Table 2, HR: 2.7, 95% CI: 0.9–8.8)
(Table 2). The expression profiles of MUC2 and MUC3 were also
considered, since these mucins had decreased expression in cancer
lesions. There was no significant change in the hazard risk with
MUC2 or MUC3 expression, although there were no deaths in
MUC5AC-negative, MUC16-negative and MUC3-positive cases
(Table 2).

Discussion
There have been two previous analyses of mucin expression in
SBC tissues in 30 cases by Zang et al. [13] and in 23 cases by Lee
et al. [14] In the present study of 60 cases, we found that increased
expression of MUC1, MUC5AC and MUC16 in SBCs was
related to poor prognostic factors such as deeper invasion, venous
invasion, lymph node metastasis, and cases in which only noncurative resection was possible. For mucins with equal expression
in SBC lesions and normal tissue, MUC4 expression was not
related to any prognostic factors, but MUC6 was related to lymph
node metastasis. Among mucins with decreased expression in
SBC, MUC2 expression was related to negative lymphatic
invasion (a favorable prognostic factor), while MUC3 was not
related to any clinicopathologic factors.
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0/1
10/15
0/13

MUC5AC(+) and/or MUC16(+), and
MUC2(+)
MUC5AC(+) and/or MUC16(+), and
MUC2(2)
MUC5AC(2) and MUC16(2), and
MUC3(+)
40.6

80.7

33.7

8.5

88.8

18.0

3/18

MUC5AC(2) and MUC16(2), and
MUC2(2)

32.5

4/6

2/11

MUC5AC(2) and MUC16(2), and
MUC2(+)

42.2

MUC5AC(+) and/or MUC16(+), and
MUC3(2)

10/16

MUC5AC(+) and/or MUC16(+)

121.3

1.9

24.2

5/29

MUC5AC(2) and MUC16(2)

6/10

2/2

Positive

161.6

MUC5AC(+) and/or MUC16(+), and
MUC3(+)

13/43

Negative

40.3

123.2

5/16

8/14

Positive

P-y

MUC5AC(2) and MUC16(2), and
MUC3(2)

7/31

Negative

*1The status of venous invasion was included as a covariate in models 1.
*2The status of lymph node metastasis was included as a covariate in models 2.
NA: not available, D/T: Deaths/Total, P-y: Person-year, HR: Hazard ratio, 95% CI: 95% confidence interval, ref.: reference.
doi:10.1371/journal.pone.0086111.t002

MUC5AC/MUC16/MUC3

MUC5AC/MUC16/MUC2

MUC5AC/MUC16

MUC16

MUC5AC

D/T

Table 2. Survival analysis for curative cases (n = 45) using a Cox proportional hazard model*.

1.8

3.1

1.0

NA

4.8

NA

0.6

1.0

5.6

1.0

7.3

1.0

3.4

1.0

HR

Model 1*1

0.5–7.0

0.8–12

ref.

1.0–23

0.1–3.9

ref.

1.8–17

ref.

1.3–42

ref.

1.2–9.8

ref.

95% CI

0.6

2.0

1.0

NA

1.7

NA

0.3

1.0

2.7

1.0

6.4

1.0

1.6

1.0

HR

Model 2*2

0.1–2.7

0.6–7.1

ref.

0.3–10

0.04–2.3

ref.

0.9–8.8

ref.

1.1–36

ref.

0.5–4.7

ref.

95% CI
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through the attenuation of E-cadherin-mediated intercellular
adhesion [28]. Thus by suppressing immune infiltration and
enhancing adhesion and invasion of tumor cell, MUC5AC might
be implicated in poor prognosis of the patients with SBC.
MUC16 is also overexpressed in many malignancies, including
ovarian, pancreatic and breast cancers [29–31] and its overexpression is associated with poor prognosis. MUC16 is also known
as a potential biomarker for the following ovarian cancer after
various therapies. Lakshmanan et al. have recently established the
functional role of MUC16 in the proliferation of breast cancer cells
[31]. Haridas et al. have also demonstrated that the increased
expression of MUC16 in progression of pancreatic cancer [30].
Similarly, in the present study we have observed overexpression of
MUC16 in 5 of 60 SBC tissues (8.3%) compared to normal small
intestine (0%). The number of MUC16 positive cases is small, but
the MUC16 expression was significantly related to poor prognosis
of the patients with SBC.
MUC4 and MUC6 showed equal expression in SBC and
normal tissue. MUC4 expression is a poor prognostic factor in
various human neoplasms [7,9], but we found no correlation
between expression of MUC4 and survival in patients with SBC.
Thus, compared with neoplasms of other organs, MUC4
expression is of little significance in SBCs, similarly to MUC1.
MUC6 is a useful marker for classification of pancreatobiliary
neoplasms [32,33]. In SBCs, however, MUC6 expression had no
impact on survival, although it was related to lymph node
metastasis.
Expression profiles of MUC2 and MUC3 were also considered,
since these mucins showed decreased expression in SBC. Our
previous studies showed that MUC2 expression is related to a
good prognosis in neoplasms of the pancreas, bile duct and
stomach [7,9]. MUC3 expression is associated with a poor
prognosis in gastric cancer [34]; however, little is currently known
about the functional role of MUC3 in cancer pathology [7]. In the
present study, there was no significant change in hazard risks with
MUC2 or MUC3 expression. It is important to note that there

were no deaths in SBC patients with a MUC5AC-negative,
MUC16-negative and MUC3-positive expression profile.
In conclusion, the results of this study demonstrate that a
MUC5AC-positive and/or MUC16-positive mucin expression
pattern is a useful marker to predict a poor outcome in patients
with SBC. This pattern differs from the expression patterns
involving MUC1, MUC2 or MUC4 that are related to a poor
prognosis in neoplasms of other organs.
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